Diagnostic imaging using a theranostic approach
Dr. Michael Samuel Hofman, Peter MacCallum Cancer Centre
In this interview, Dr. Hofman highlights the benefits of a theranostic approach. He further discusses the advantages of using Gallium as a radiotracer and explains why peptides are gaining increased attention as potential ligands in radiotracer and radioligand therapies. Concluding his talk, he shares his expert perspective on the optimal range for maximum standardized uptake value (SUV).
Targeting the CA IX surface protein
Dr. Darren R. Feldman - Memorial Sloan Kettering Cancer Center
In this interview, Dr. Feldman presents the merits of a theranostic approach for patients battling difficult-to-treat cancers. He further discusses the strengths of employing a CA IX-targeted strategy and shares his insights on the preliminary data from Part A of the GaLuCi Trial. Additionally, he explores how the CA IX radiotracer could significantly influence patient outcomes during the diagnostic phase.
Discover the latest GaLuCi Trial results
First-in-human safety, imaging and dosimetry of Debiopharm’s PET imaging agent (gallium-labelled, Debio 0328) a novel CA IX targeting peptide, in patients with clear cell renal cell carcinoma.
Leveraging the power of Radioligand Therapy
Radioligand therapy (RLT) is a proven, exciting new modality that combines both precision medicine ‘You-treat-what-you-see’ approach and targeted therapy. The theranostic treatment approach has been shown to be effective and well-tolerated as it allows the treatment of only patients who express the right tumor biomarker.¹⁻⁴
Responding to high unmet needs
Current overall survival and patient outcomes are insufficient in advanced clear cell renal cell carcinoma (ccRCC), Metastatic pancreatic ductal adenocarcinoma (PDAC) and metastatic colorectal cancer (CRC). Radioligand therapy has the potential to transform outcomes for these patients.10-30
Debiopharm’s theranostic pair is formed of a first-in-class radiopeptide (177Lu-labelled, D0228) combined with a PET imaging agent (68Ga-labelled, D0328) targeting the CA IX biomarker.5-9 The therapy is currently being investigated in the GaLuCi study, a first-in-human multicenter, non-randomized phase 1/2 clinical trial assessing safety and tolerability, imaging characteristics and the efficacy of the theranostic pair Debio 0228/0328 in patients with unresectable, locally advanced or metastatic solid tumors.